Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2017 (2017), Article ID 1683060, 6 pages
https://doi.org/10.1155/2017/1683060
Review Article

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

1Research Unit Phase I Trials, ASST Monza, Monza, Italy
2Oncology Unit, ASST Monza, Monza, Italy
3Haematology and Oncology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy
4Oncology Unit, ASST Ovest Milanese, Legnano, Italy
5Oncology Day Hospital Unit, Ospedale Civile di Guastalla, Guastalla, Italy
6Oncology Unit, Ospedale Vito Fazzi, Lecce, Italy
7Oncology Unit, ASST Rhodense-Presidio di Garbagnate Milanese e Presidio di Rho, Garbagnate, Italy
8Oncology Unit, ASST Lecco, Lecco, Italy
9Oncology Unit, ASST Lariana, Como, Italy
10Oncology Unit, ASST della Valle Olona, Saronno, Italy
11Oncology Day Hospital Unit, Azienda USL Romagna, Cattolica, Italy
12Oncology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy
13Oncology Unit, ASST della Valle Olona, Busto Arsizio, Italy
14Oncology Unit, ASST Melegnano-Martesana, Gorgonzola, Italy
15Methodology for Clinical Research Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy

Correspondence should be addressed to M. E. Cazzaniga; ti.aznom-tssa@aginazzac.aniram

Received 12 June 2017; Accepted 8 November 2017; Published 3 December 2017

Academic Editor: Eleanor E. R. Harris

Copyright © 2017 M. E. Cazzaniga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. André and C. C. Zielinski, “Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents,” Annals of Oncology, vol. 23, no. 6, Article ID mds195, pp. vi46–vi51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. K. R. Bauer, M. Brown, R. D. Cress, C. A. Parise, and V. Caggiano, “Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype,” Cancer, vol. 109, no. 9, pp. 1721–1728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Di Desidero, R. S. Kerbel, and G. Bocci, “Metronomic chemotherapy for triple negative breast cancer?” AGING, vol. 8, no. 4, pp. 573-574, 2016. View at Publisher · View at Google Scholar
  4. I. Kareva, D. J. Waxman, and G. L. Klement, “Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance,” Cancer Letters, vol. 358, no. 2, pp. 100–106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Colleoni, K. P. Gray, S. Gelber et al., “Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00,” Journal of Clinical Oncology, vol. 34, no. 28, pp. 3400–3408, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Pruneri, K. P. Gray, A. Vingiani et al., “Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00,” Breast Cancer Research and Treatment, vol. 158, no. 2, pp. 323–331, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. K. E. Nasr, M. A. Osman, M. S. Elkady et al., “Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: A phase III study,” Annals of Translational Medicine, vol. 3, no. 19, 284 pages, 2015. View at Google Scholar
  8. N. Masuda, K. Higaki, T. Takano et al., “A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2- negative primary breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 74, no. 2, pp. 229–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Shawky and S. Galal, “Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy - A single-arm phase II study,” Journal of the Egyptian National Cancer Institute, vol. 26, no. 4, pp. 195–202, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. H. A. Alagizy, M. A. Shehata, T. A. Hashem, K. K. Abdelaziz, and M. M. Swiha, “Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer,” Hematology/Oncology and Stem Cell Therapy, vol. 8, no. 1, pp. 22–27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Yoshimoto, S. Takao, M. Hirata et al., “Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: A phase II study in patients with HER2-negative metastatic breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 70, no. 2, pp. 331–338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Wang, J. Ren, J. Zhang et al., “Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45),” Clinical and Translational Oncology, vol. 18, no. 1, pp. 82–87, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Kummar, J. L. Wade, A. M. Oza et al., “Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer,” Investigational New Drugs, vol. 34, no. 3, pp. 355–363, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Di Desidero, P. Xu, S. Man, G. Bocci, and R. S. Kerbel, “Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer,” Oncotarget , vol. 6, no. 40, pp. 42396–42410, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Kontani, S. I. Hashimoto, C. Murazawa et al., “Indication of metronomic chemotherapy for metastatic breast cancer: clinical outcomes and responsive subtypes,” Molecular and Clinical Oncology, vol. 4, no. 6, pp. 947–953, 2016. View at Google Scholar
  16. M. E. Cazzaniga, L. Cortesi, A. Ferzi et al., “Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study,” Breast Cancer Research and Treatment, vol. 160, no. 3, pp. 501–509, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Twelves, A. Awada, J. Cortes et al., “Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer,” Breast Cancer: Basic and Clinical Research, vol. 10, pp. 77–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Hamilton, G. Kimmick, J. Hopkins et al., “Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer,” Clinical Breast Cancer, vol. 13, no. 6, pp. 416–420, 2013. View at Publisher · View at Google Scholar · View at Scopus